Fig. 6

PLAU and TM4SF1 interaction leads to activation of Akt signaling to promote NSCLC cell growth and survival. (A, B) Western blot analysis of phosphorylated Akt (p-Akt) and total Akt in NSCLC cells transfected with indicated plasmids. (C) NSCLC cells were co-transfected with PLAU and TM4SF1 and treated with the Akt inhibitor MK2206. Cell proliferation was determined by cell counting. ^*P < 0.05. (D) Colony formation assay in NSCLC cells co-transfected with PLAU and TM4SF1 and treated with the Akt inhibitor MK2206. ^*P < 0.05. (E) Western blot analysis of PLAU protein expression in NSCLCs with indicated treatments. (F) NSCLC cells were co-transfected with PLAU and TM4SF1 and treated with the Akt inhibitor MK2206. Cell apoptosis was measured after culturing in the presence or absence of serum for 48 h. ^*P < 0.05. (G) NSCLC cells were co-transfected with PLAU and TM4SF1 and treated with the Akt inhibitor MK2206. The cells were tested for viability after exposure to different concentrations of cisplatin for 72 h